Clinical Trial Update: DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating DMP115 as a contrast echocardiography agent to assess heart function in patients with reduced ejection fraction (25-40%) has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• DMP115

Snippet

Sponsor: Lantheus Medical Imaging | Conditions: Ventricular Ejection Fraction | Phase 4 | Status: COMPLETED